Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and lacks oestrogen receptor (ER), progesterone receptor (PR) expression, and human epidermal growth factor receptor 2 (HER2) amplification. This evidence concerns the gene ESR1 and breast carcinoma.